Transcend Capital Advisors LLC Acquires 3,000 Shares of Becton, Dickinson and Company (NYSE:BDX)

Transcend Capital Advisors LLC increased its holdings in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) by 109.9% in the first quarter, according to its most recent disclosure with the SEC. The firm owned 5,729 shares of the medical instruments supplier's stock after purchasing an additional 3,000 shares during the period. Transcend Capital Advisors LLC's holdings in Becton, Dickinson and Company were worth $1,312,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also bought and sold shares of the company. REAP Financial Group LLC boosted its holdings in shares of Becton, Dickinson and Company by 75.3% during the fourth quarter. REAP Financial Group LLC now owns 128 shares of the medical instruments supplier's stock worth $29,000 after acquiring an additional 55 shares during the period. Alpine Bank Wealth Management acquired a new stake in Becton, Dickinson and Company during the 1st quarter worth approximately $29,000. Picton Mahoney Asset Management lifted its holdings in Becton, Dickinson and Company by 61.4% during the 4th quarter. Picton Mahoney Asset Management now owns 142 shares of the medical instruments supplier's stock worth $32,000 after purchasing an additional 54 shares during the last quarter. Nexus Investment Management ULC bought a new stake in Becton, Dickinson and Company in the 1st quarter valued at $34,000. Finally, Hopwood Financial Services Inc. acquired a new position in Becton, Dickinson and Company in the 4th quarter valued at $39,000. Institutional investors own 86.97% of the company's stock.

Analyst Ratings Changes

A number of research firms have recently weighed in on BDX. Piper Sandler downgraded Becton, Dickinson and Company from an "overweight" rating to a "neutral" rating and dropped their target price for the stock from $260.00 to $185.00 in a report on Friday, May 2nd. The Goldman Sachs Group downgraded shares of Becton, Dickinson and Company from a "buy" rating to a "neutral" rating and set a $192.00 price objective for the company. in a report on Friday, May 2nd. Citigroup downgraded shares of Becton, Dickinson and Company from a "strong-buy" rating to a "hold" rating and cut their price objective for the company from $217.00 to $185.00 in a report on Thursday, May 22nd. Barclays cut their price objective on shares of Becton, Dickinson and Company from $261.00 to $241.00 and set an "overweight" rating for the company in a report on Tuesday, June 3rd. Finally, Wells Fargo & Company downgraded shares of Becton, Dickinson and Company from an "overweight" rating to an "equal weight" rating in a report on Thursday, May 1st. Eight investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Hold" and a consensus price target of $219.22.

Becton, Dickinson and Company Stock Performance

Shares of Becton, Dickinson and Company stock opened at $170.83 on Friday. The company has a 50 day moving average of $176.53 and a 200-day moving average of $209.51. Becton, Dickinson and Company has a 1-year low of $163.33 and a 1-year high of $251.99. The company has a current ratio of 1.13, a quick ratio of 0.64 and a debt-to-equity ratio of 0.70. The company has a market cap of $48.96 billion, a PE ratio of 32.60, a price-to-earnings-growth ratio of 1.28 and a beta of 0.25.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The medical instruments supplier reported $3.35 earnings per share for the quarter, topping analysts' consensus estimates of $3.28 by $0.07. Becton, Dickinson and Company had a net margin of 7.28% and a return on equity of 15.99%. The company had revenue of $5.27 billion during the quarter, compared to the consensus estimate of $5.35 billion. During the same quarter in the prior year, the firm posted $3.17 EPS. The firm's quarterly revenue was up 4.5% on a year-over-year basis. As a group, equities research analysts forecast that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, June 30th. Stockholders of record on Monday, June 9th will be issued a dividend of $1.04 per share. This represents a $4.16 dividend on an annualized basis and a dividend yield of 2.44%. The ex-dividend date is Monday, June 9th. Becton, Dickinson and Company's dividend payout ratio (DPR) is presently 79.39%.

Insider Transactions at Becton, Dickinson and Company

In related news, EVP Michael David Garrison sold 479 shares of the stock in a transaction that occurred on Wednesday, April 9th. The shares were sold at an average price of $197.28, for a total value of $94,497.12. Following the completion of the transaction, the executive vice president now owns 4,887 shares of the company's stock, valued at $964,107.36. This represents a 8.93% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP David Shan sold 1,166 shares of the stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $171.19, for a total transaction of $199,607.54. Following the completion of the transaction, the executive vice president now directly owns 4,575 shares of the company's stock, valued at approximately $783,194.25. The trade was a 20.31% decrease in their position. The disclosure for this sale can be found here. 0.36% of the stock is currently owned by insiders.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.